Table 3

Patient characteristics

Number of patients30
Age, median (range)53 (31–75)
Menopausal status
 Premenopausal13 (43%)
 Postmenopausal17 (57%)
Disease stage
 I3 (10%)
 II6 (20%)
 III4 (13%)
 IV17 (57%)
Hormone receptor expression of primary tumor
 ER+PR+6 (20%)
 ER+PR−7 (23%)
 ER−PR+4 (13%)
 ER−PR−11 (37%)
 Unknown2 (7%)
HER-2 expression of primary tumor
 3+6 (20%)
 2+4 (13%)
 1+5 (17%)
 014 (47%)
 Unknown1 (3%)
Prior treatment
 Surgery30 (100%)
 Radiation18 (60%)
 Hormonal therapy12 (40%)
 Chemotherapy30 (100%)
  adjuvant22 (73%)
  neoadjuvant7 (23%)
  1st line metastatic17 (57%)
  ≥2nd line metastatic10 (33%)